-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The 2020 Required Papers on Urological Oncology at the Virtual Annual Meeting of the European Urological Association (EAU) Oncology Urology (ESOU) in 2021 includes a comprehensive summary of important papers in the urethra literature by Dr Thomas Seisen.
's first article is the DaBlaCa-13 study, which aims to assess tumor reactions and adverse events compared to patients with relapsed nonmuscular leaching bladder cancer (NMIBC) using fissromycin C for short-term, intensive chemotherapy compared to auxiliary infusions.
intervention group (59 cases) patients received fissromycin C 3 times a week in random groups for a total of 2 weeks (59 cases), control group with urethra bladder tumor excision (TURBT) and 6 doses of auxiliary drips per week (61 cases).
result is a tumor response, assessed in the intervention group after 4 weeks of treatment with a flexible cystoscopy.
DaBlaCa-13 trial found that 33 participants (57 percent) in the intervention group observed a complete tumor response and reported fewer adverse events in the intervention group than in the control group.
these results are instructive, given that chemical cutting produces tumor responses in 57% of patients, only half of patients receiving chemotherapy do need TURBT.
second article, the NIMBUS III trial, published in the European Journal of Urology in 2020, uses standard quantities and doses of Bacillus Calmette-Guérin (BCG) drips with... MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Mets Medicine" or "Source: MedSci Originals" are owned by Mets Medicine and are not authorized to be reproduced by any media, website or individual, and are authorized to be reproduced with the words "Source: Mets Medicine".
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here
